FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

Proton pump inhibitors, or PPIs, are among the most commonly used medications around the world. They are often taken to ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

The 61-year-old man received a new kidney from a deceased donor after being diagnosed with “nephrosclerosis-related end-stage ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

In a first step toward FDA approval of kidney xenotransplantation, a living human with end-stage kidney disease may receive a ...

One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles.

Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

The FDA has granted Orphan Drug designation to riliprubart for the investigational treatment of AMR in solid organ transplantation.